2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100935R
    Cimaterol (Standard) 54239-37-1
    Cimaterol (Standard) is the analytical standard of Cimaterol. This product is intended for research and analytical applications. Cimaterol (CL 263780) is a β-adrenergic agonist on energy metabolism in ob/ob mice. The Kd for Cimaterol binding to the L6 β-receptor is 26 nM which is compatible with its EC50 for the stimulation of protein synthesis (approx 5 nM).
    Cimaterol (Standard)
  • HY-101020R
    Picolinamide (Standard) 1452-77-3 98%
    Picolinamide (Standard) is the analytical standard of Picolinamide. This product is intended for research and analytical applications. Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells.
    Picolinamide (Standard)
  • HY-101180A
    (E/Z)-C2 Ceramide 195194-58-2 98%
    (E/Z)-C2 Ceramide is a ceramide.
    (E/Z)-C2 Ceramide
  • HY-101317A
    TAN-67 148545-09-9 98%
    TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.
    TAN-67
  • HY-101325B
    BRL-37344 114333-71-0 98%
    BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes.
    BRL-37344
  • HY-101738A
    Peliglitazar racemate 331744-72-0 98%
    Peliglitazar racemate is the racemate of Peliglitazar. Peliglitazar is a novel dual α/γ PPAR activator.
    Peliglitazar racemate
  • HY-101873R
    Atorvastatin lactone (Standard) 125995-03-1
    Atorvastatin lactone (Standard) is the analytical standard of Atorvastatin lactone. This product is intended for research and analytical applications. Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
    Atorvastatin lactone (Standard)
  • HY-101873S
    Atorvastatin lactone-d5 98%
    Atorvastatin lactone-d5 is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
    Atorvastatin lactone-d5
  • HY-101930B
    (R)-BMS-816336 1009583-83-8 98%
    (R)-BMS-816336 (Compound 6n-1) is a potent and orally active inhibitor of human, mouse and cynomolgus monkey 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC50s of 14.5 nM, 50.3 nM and 16 nM, respectively .
    (R)-BMS-816336
  • HY-10284S1
    Linagliptin-13C,d3 1398044-43-3 98%
    Linagliptin-13C,d3 is the 13C- and deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. Linagliptin-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Linagliptin-13C,d3
  • HY-10284S3
    Linagliptin-d3-1 1398044-48-8 98%
    Linagliptin-d3-1 (BI 1356-d3-1) is the deuterium labeled Linagliptin (HY-10284). Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
    Linagliptin-d3-1
  • HY-103151A
    CP94253 131084-35-0 98%
    CP94253 is an orally active, brain-penetrant and selective 5-HT1B receptor agonist with an Ki of 2 nM. CP94253 induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 can be used for the research of depression and heightened aggressive behavior.
    CP94253
  • HY-10450AR
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) 960404-48-2 98%
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard)
  • HY-10450S3
    Dapagliflozin-13C6 98%
    Dapagliflozin-13C6 (BMS-512148-13C6) is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin-13C6
  • HY-10451S2
    Canagliflozin-d6 98%
    Canagliflozin-d6 is the deuterium labeled Canagliflozin. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
    Canagliflozin-d6
  • HY-105185B
    (Rac)-Fidarestat 105300-43-4
    (Rac)-Fidarestat ((Rac)-SNK 860) is the racemate of Fidarestat (HY-105185). (Rac)-Fidarestat is a potent aldose reductase inhibitor.
    (Rac)-Fidarestat
  • HY-105191A
    Azalanstat dihydrochloride 143484-82-6 98%
    Azalanstat dihydrochloride (RS-21607 dihydrochloride) is an inhibitor of heme oxygenase and lanosterol 14α-demethylase, with inhibitory activity against HO-1 (IC50 = 5.5 µM) and HO-2 (IC50 = 24.5 µM). Azalanstat dihydrochloride reduces the maturation rate of rat oocytes, increases rat oocyte degeneration, and partially inhibits progesterone production in preovulatory follicles of rats.
    Azalanstat dihydrochloride
  • HY-105286A
    BI-135585 hydrate 1374032-89-9 98%
    BI-135585 hydrate is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 hydrate exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 hydrate can be used for type 2 diabetes research.
    BI-135585 hydrate
  • HY-105829S
    Sulfatroxazole-d4 98%
    Sulfatroxazole-d4 (Isosulfafurazole-d4) is the deuterium labeled Sulfatroxazole (HY-105829). Sulfatroxazole (Isosulfafurazole) (compound 12) is a selective antagonist of ETA receptor (IC50 of 0.26 μM).
    Sulfatroxazole-d4
  • HY-10585AG
    Valproic acid sodium (GMP) 1069-66-5 98%
    Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid sodium (GMP)
Cat. No. Product Name / Synonyms Application Reactivity